Merus (NASDAQ:MRUS) Shares Sold by Driehaus Capital Management LLC

Driehaus Capital Management LLC lessened its position in shares of Merus (NASDAQ:MRUS - Free Report) by 5.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,280,337 shares of the biotechnology company's stock after selling 78,631 shares during the quarter. Driehaus Capital Management LLC owned approximately 1.87% of Merus worth $53,838,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRUS. Baker BROS. Advisors LP boosted its stake in shares of Merus by 50.0% during the 4th quarter. Baker BROS. Advisors LP now owns 450,000 shares of the biotechnology company's stock worth $18,922,000 after acquiring an additional 150,000 shares in the last quarter. Algert Global LLC grew its holdings in Merus by 12.6% in the fourth quarter. Algert Global LLC now owns 173,114 shares of the biotechnology company's stock valued at $7,279,000 after purchasing an additional 19,390 shares during the period. Alyeska Investment Group L.P. purchased a new stake in shares of Merus in the fourth quarter valued at approximately $5,734,000. Allostery Investments LP acquired a new position in shares of Merus during the 4th quarter worth approximately $914,000. Finally, Boxer Capital Management LLC purchased a new position in shares of Merus during the 4th quarter valued at approximately $79,895,000. Hedge funds and other institutional investors own 96.14% of the company's stock.

Merus Trading Down 3.4 %

NASDAQ:MRUS traded down $1.45 during trading hours on Friday, hitting $41.32. The company's stock had a trading volume of 556,197 shares, compared to its average volume of 719,048. Merus has a 52-week low of $33.19 and a 52-week high of $61.61. The stock has a market capitalization of $2.86 billion, a P/E ratio of -10.46 and a beta of 0.94. The stock has a fifty day moving average of $43.51 and a 200-day moving average of $44.10.

Merus (NASDAQ:MRUS - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.23). The business had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. On average, sell-side analysts forecast that Merus will post -3.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. William Blair reissued an "outperform" rating on shares of Merus in a report on Monday, April 28th. Wells Fargo & Company reduced their price target on shares of Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a research report on Thursday. Bank of America decreased their price target on shares of Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. HC Wainwright reiterated a "buy" rating and set a $85.00 price objective on shares of Merus in a research note on Monday, March 3rd. Finally, Piper Sandler started coverage on Merus in a research report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price on the stock. One research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $85.15.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.